North America Hemoglobinopathies Market Size & Outlook
North America hemoglobinopathies market, 2018-2030 (US$M)
Related Markets
North America hemoglobinopathies market highlights
- The North America hemoglobinopathies market generated a revenue of USD 3,125.1 million in 2022.
- The market is expected to grow at a CAGR of 11.6% from 2023 to 2030.
- In terms of segment, sickle cell disease was the largest revenue generating disease type in 2022.
- Sickle cell disease is the most lucrative disease type segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2023 to 2030.
North America data book summary
| Market revenue in 2022 | USD 3,125.1 million |
| Market revenue in 2030 | USD 7,529.7 million |
| Growth rate | 11.6% (CAGR from 2022 to 2030) |
| Largest segment | Sickle cell disease |
| Fastest growing segment | Sickle cell disease |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Thalassemia, Sickle cell disease, Other Hb Variants |
| Key market players worldwide | Sangamo Therapeutics Inc, Global Blood Therapeutics, Bluebird bio Inc, Emmaus Life Sciences Inc, Pfizer Inc, Novartis AG ADR, Prolong Pharmaceuticals, Bioverativ, Gamida Cell, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, North America region accounted for 20.0% of the global hemoglobinopathies market in 2022.
- Globally, Europe is projected to lead the regional market in terms of revenue in 2030.
- Europe is the fastest growing regional market and is projected to reach USD 7,529.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hemoglobinopathies Market Scope
Hemoglobinopathies Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America hemoglobinopathies market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemoglobinopathies market will help companies and investors design strategic landscapes.
Sickle cell disease was the largest segment with a revenue share of 59.29% in 2022. Horizon Databook has segmented the North America hemoglobinopathies market based on thalassemia, sickle cell disease, other hb variants covering the revenue growth of each sub-segment from 2018 to 2030.
North America encompasses the U.S. and Canada. Key drivers of the market include increasing awareness of hemoglobinopathies among patients and improving healthcare facilities. Various organizations spread awareness by conducting different programs.
Its membership includes research, public health, and provider organizations, faith-based organizations, industry representatives, foundations, patient groups, and federal agencies. Increasing immigration to North America and improving diagnosis & treatment for common and rare genetic diseases, such as thalassemia and Sickle Cell Disease (SCD), are expected to fuel the market growth for hemoglobinopathies in this region.
Growing number of COVID-19 cases is not anticipated to impact the demand for diagnostic products. However, panic buying situations and lesser API deliveries from China can impact production and availability of drugs in the market.
Reasons to subscribe to North America hemoglobinopathies market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America hemoglobinopathies market databook
-
Our clientele includes a mix of hemoglobinopathies market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America hemoglobinopathies market , including forecasts for subscribers. This continent databook contains high-level insights into North America hemoglobinopathies market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America hemoglobinopathies market size, by country, 2018-2030 (US$M)
North America Hemoglobinopathies Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
